SearchDictionaryMobileLogin

Maurie Markman Selected Research

Drug Therapy (Chemotherapy)

04/2008Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
04/2008Evidence-based chemotherapy administration in advanced ovarian cancer: An impressive past, a disquieting present and an uncertain future.
01/2008Commentary entitled "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials".
01/2008Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
11/2007Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
09/2007Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions.
08/2007Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
08/2007Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
07/2007Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer.
01/2007Intraperitoneal chemotherapy in the management of ovarian cancer.
11/2006The role of intraperitoneal chemotherapy in ovarian cancer.
08/2006Chemotherapy-induced peripheral neuropathy: underreported and underappreciated.
05/2006Palliative chemotherapy "near the end-of-life" in ovarian cancer: not necessarily "aggressive cure-oriented therapy".
02/2006Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.
01/2006Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.
05/2005Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists.
04/2005Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
01/2005Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
01/2005A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
12/2004Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers.
08/2004Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
07/2004Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
04/2004Intraperitoneal hyperthermic chemotherapy as treatment of peritoneal carcinomatosis of colorectal cancer.
03/2004Duration of chemotherapy in low-versus high-volume metastatic cancer: should there be a difference?
02/2004Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
01/2004Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?
11/2003Consolidation/maintenance chemotherapy for ovarian cancer.
08/2003Optimizing primary chemotherapy in ovarian cancer.
07/2003Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
04/2003Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
12/2002ICON3 and chemotherapy for ovarian cancer.
08/2002Progress in preventing chemotherapy-induced nausea and vomiting.
02/2002Role of chemotherapy in the management of ovarian cancer.
02/2002Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.

Articles by Research Topic

Disease

46Ovarian Neoplasms (Ovarian Cancer)
04/2008 - 02/2002
16Neoplasms (Cancer)
06/2007 - 06/2002
12Carcinoma (Carcinomatosis)
05/2008 - 02/2002
6Hypersensitivity (Allergy)
11/2007 - 02/2002
4Endometrial Neoplasms (Endometrial Cancer)
09/2005 - 06/2003
3Peripheral Nervous System Diseases (PNS Diseases)
08/2006 - 01/2004
2Neutropenia
02/2004 - 10/2003
2Fallopian Tube Neoplasms
01/2004 - 12/2003
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2007
1Carcinosarcoma
02/2007
1Adenocarcinoma
03/2005
1Thrombocytopenia (Thrombopenia)
12/2004
1Sunburn
08/2004
1Colorectal Neoplasms (Colorectal Cancer)
04/2004
1Arthralgia (Joint Pain)
11/2003
1Radiodermatitis
11/2003
1Vomiting
08/2002
1Nausea
08/2002
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
04/2002

Drug/Important Bio-Agent (IBA)

25Paclitaxel (Taxol)FDA LinkGeneric
05/2008 - 05/2002
23Carboplatin (JM8)FDA LinkGeneric
05/2008 - 02/2002
13PlatinumIBA
01/2008 - 05/2002
6pegylated liposomal doxorubicinIBA
01/2008 - 11/2003
5gemcitabineFDA Link
02/2006 - 02/2002
3CA-125 Antigen (CA 125 Antigen)IBA
10/2006 - 07/2003
3Topotecan (Hycamtin)FDA Link
08/2006 - 10/2004
2IfosfamideFDA LinkGeneric
02/2007 - 04/2002
2Doxorubicin (Adriamycin)FDA LinkGeneric
02/2006 - 08/2004
2Recombinant ErythropoietinIBA
01/2006 - 09/2002
2taxaneIBA
10/2004 - 06/2004
2Cisplatin (Platino)FDA LinkGeneric
10/2004 - 04/2002
2TamoxifenFDA LinkGeneric
08/2004 - 05/2004
2irinotecan (Camptosar)FDA LinkGeneric
01/2004 - 05/2003
1Recombinant Interferon-gamma (Interferon gamma, Recombinant)FDA Link
05/2008
11-dodecylpyridoxal (PLD)IBA
01/2008
1AntigensIBA
11/2007
1Papillomavirus Vaccines (HPV Vaccines)IBA
06/2007
1Antineoplastic Agents (Antineoplastics)IBA
02/2007
1polilactofateIBA
11/2006
1Etoposide (VP 16)FDA LinkGeneric
08/2006
1TaxoidsIBA
08/2006
1Interferon-alpha (Interferon Alfa)FDA Link
01/2006
1Amifostine (Ethyol)FDA LinkGeneric
03/2005
1vinorelbine (Navelbine)FDA LinkGeneric
12/2004
1ErythropoietinIBA
10/2004
1Interferon-betaIBA
01/2004
1docetaxel (Taxotere)FDA Link
12/2003
1Danazol (Azol)FDA LinkGeneric
06/2003
1Bleomycin (Blenoxane)FDA LinkGeneric
04/2002

Therapy/Procedure

34Drug Therapy (Chemotherapy)
04/2008 - 02/2002
1Complementary Therapies (Alternative Medicine)
01/2007
1Microspheres (Microsphere)
11/2006
1Combination Drug Therapy (Combination Chemotherapy)
10/2003